Eye Disease disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EYD002 MIFTS: 58	Eye Disease Categories: Eye diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Eye Disease

MalaCards integrated aliases for Eye Disease:

Name: Eye Disease ¹² ¹⁵ ¹⁷

Eye Diseases ⁵⁴ ⁴² ¹⁵

Abnormality of the Eye ²⁹ ⁶

Classifications:

MalaCards categories:
Anatomical: Neuronal diseases Eye diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Diseases of the eye and adnexa

Disorders of vitreous body and globe

Disorders of globe

External Ids:

Disease Ontology ¹² DOID:5614

ICD9CM ³⁴ 379.90

MeSH ⁴³ D005128

NCIt ⁴⁹ C26767

SNOMED-CT ⁶⁷ 371405004

ICD10 ³² H44

EFO ¹⁷ EFO_0003966

UMLS ⁷¹ C0015397

Sources

Summaries for Eye Disease

MedlinePlus : ⁴² Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pinkeye Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute

MalaCards based summary : Eye Disease, also known as eye diseases, is related to macular degeneration, age-related, 1 and retinitis pigmentosa. An important gene associated with Eye Disease is CNGB3 (Cyclic Nucleotide Gated Channel Subunit Beta 3), and among its related pathways/superpathways are Immune response Lectin induced complement pathway and Creation of C4 and C2 activators. The drugs Propylthiouracil and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include eye, thyroid and testes, and related phenotypes are cardiovascular system and nervous system

Disease Ontology : ¹² An eye and adnexa disease that is located in the eye.

Sources

Related Diseases for Eye Disease

Diseases related to Eye Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 774)

#	Related Disease	Score	Top Affiliating Genes
1	macular degeneration, age-related, 1	34.5	VEGFA TNF RDH12 IMPG2 HTRA1 ERCC6
2	retinitis pigmentosa	34.0	VPS13B VEGFA TNF RDH12 NPHP1 IMPG2
3	retinal disease	34.0	RDH12 IMPG2 CNGB3 CNGA3 CFH CFB
4	corneal disease	33.2	VEGFA TNF LCAT ERCC6
5	retinoschisis 1, x-linked, juvenile	33.1	CNGB3 CNGA3 CACNA1F ABCA4
6	senior-loken syndrome 1	32.7	RDH12 NPHP1 ABCA4
7	yemenite deaf-blind hypopigmentation syndrome	32.6	VEGFA CFH ABCA4
8	macular degeneration, age-related, 6	32.5	CFH CFB ABCA4
9	macular degeneration, age-related, 4	32.5	CFH CFB ABCA4
10	lens disease	32.4	VEGFA TNF ERCC6
11	leber congenital amaurosis 1	32.3	RDH12 CNGB3 CNGA3
12	cogan syndrome	32.2	NPHP1 CACNA1F
13	macular degeneration, age-related, 14	32.1	CFB C2
14	pathologic nystagmus	31.8	RDH12 CNGB3 CNGA3 CACNA1F ABCA4
15	leber plus disease	31.7	RDH12 NPHP1 IMPG2 CNGB3 CNGA3 CACNA1F
16	kuhnt-junius degeneration	31.7	VEGFA HTRA1 CFH CFB ARMS2
17	congenital stationary night blindness	31.6	RDH12 CNGB3 CNGA3 CACNA1F ABCA4
18	pigmented paravenous chorioretinal atrophy	31.5	RDH12 ABCA4
19	chronic kidney disease	31.5	VEGFA TNF NPHP1 LCAT CFH
20	stargardt disease	31.4	RDH12 IMPG2 CNGB3 CNGA3 CFH ARMS2
21	color blindness	31.3	CNGB3 CNGA3 ABCA4
22	cone-rod dystrophy 2	31.1	TNF RDH12 CNGB3 CNGA3 CACNA1F ABCA4
23	angioid streaks	31.1	VEGFA CFH ARMS2 ABCC6
24	achromatopsia	31.1	RDH12 CNGB3 CNGA3 CACNA1F ABCA4
25	scotoma	31.0	VEGFA CNGB3 CNGA3 ABCA4
26	hemolytic anemia	30.9	TNF LCAT CFH CFB C3
27	lyme disease	30.9	TNF CFH C3
28	hemolytic-uremic syndrome	30.9	CFH CFB C3 C2
29	membranoproliferative glomerulonephritis	30.9	LCAT CFH CFB C3
30	choroideremia	30.9	CNGB3 CNGA3 ABCA4
31	end stage renal disease	30.8	VEGFA TNF CFH C3
32	pseudoxanthoma elasticum	30.8	VEGFA CFH ABCC6 ABCA4
33	cone-rod dystrophy 3	30.8	ERCC6 CACNA1F ABCA4
34	solar retinopathy	30.7	RDH12 IMPG2 ABCA4
35	peripheral vascular disease	30.7	VEGFA LCAT ERCC6
36	achromatopsia 3	30.7	CNGB3 CNGA3 CACNA1F
37	fundus albipunctatus	30.6	RDH12 CACNA1F ABCA4
38	central serous chorioretinopathy	30.6	CFH ARMS2
39	diarrhea	30.6	TNF CFH CFB C3
40	degenerative myopia	30.6	VEGFA ARMS2
41	cone dystrophy	30.6	CNGB3 CNGA3 ABCA4
42	eales disease	30.4	VEGFA TNF
43	fish-eye disease	12.6
44	aland island eye disease	12.6
45	bornholm eye disease	12.5
46	rare genetic eye disease	12.1
47	visual impairment and progressive phthisis bulbi	11.7
48	fundus dystrophy	11.6	VPS13B VEGFA RDH12 NPHP1 IMPG2 HTRA1
49	degeneration of macula and posterior pole	11.4	VEGFA HTRA1 ERCC6 CFH CFB C3
50	eye degenerative disease	11.4	VEGFA RDH12 ERCC6 CNGB3 CNGA3 CFH

Graphical network of the top 20 diseases related to Eye Disease:

Sources

Symptoms & Phenotypes for Eye Disease

MGI Mouse Phenotypes related to Eye Disease:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cardiovascular system	MP:0005385	10.02	ABCA4 ABCC6 C3 CFB CFH CNGA3
2	nervous system	MP:0003631	10	ABCA4 C3 CACNA1F CFH CNGA3 CNGB3
3	renal/urinary system	MP:0005367	9.7	ABCC6 C3 CFB CFH LCAT NPHP1
4	skeleton	MP:0005390	9.61	ABCA4 C3 CACNA1F CFB ERCC6 HTRA1
5	vision/eye	MP:0005391	9.47	ABCA4 ABCC6 C3 CACNA1F CFH CNGA3

Sources

Drugs & Therapeutics for Eye Disease

Drugs for Eye Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 395)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Propylthiouracil

Approved, Investigational

Phase 4

51-52-5

657298

Fluorouracil

Approved

Phase 4

51-21-8

3385

Ketorolac

Approved

Phase 4

66635-83-4, 74103-06-3

3826

Azithromycin

Approved

Phase 4

83905-01-5

447043 55185

Mineral oil

Approved, Vet_approved

Phase 4

8042-47-5

Ethanol

Approved

Phase 4

64-17-5

702

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Doxycycline

Approved, Investigational, Vet_approved

Phase 4

564-25-0

54671203

Dinoprost

Approved, Investigational

Phase 4

551-11-1

5283078

Dinoprost tromethamine

Approved, Vet_approved

Phase 4

38562-01-5

5282415

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

5754

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Dorzolamide

Approved

Phase 4

120279-96-1

5284549 3154

Glycerol

Approved, Investigational

Phase 4

56-81-5

753

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Methimazole

Approved

Phase 4

60-56-0

1349907

Sulfacetamide

Approved

Phase 4

144-80-9

5320

Dipivefrin

Approved

Phase 4

52365-63-6

3105

Menthol

Approved

Phase 4

2216-51-5

16666

Moxifloxacin

Approved, Investigational

Phase 4

354812-41-2, 151096-09-2

152946

Propranolol

Approved, Investigational

Phase 4

525-66-6

4946

Povidone

Approved

Phase 4

9003-39-8

Sorbitol

Approved

Phase 4

50-70-4

5780

Isotretinoin

Approved

Phase 4

4759-48-2

5282379 5538

Metoprolol

Approved, Investigational

Phase 4

37350-58-6, 51384-51-1

4171

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 4

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 4

50-02-2

5743

Diclofenac

Approved, Vet_approved

Phase 4

15307-86-5

3033

Levoleucovorin

Approved, Investigational

Phase 4

68538-85-2

Spiramycin

Approved

Phase 4

24916-50-5

Sulfadiazine

Approved, Investigational, Vet_approved

Phase 4

68-35-9

5215

Pyrimethamine

Approved, Investigational, Vet_approved

Phase 4

58-14-0

4993

Verteporfin

Approved, Investigational

Phase 4

129497-78-5

Eplerenone

Approved

Phase 4

107724-20-9

150310 443872

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741

Fluorometholone

Approved, Investigational

Phase 4

426-13-1

9878

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

6741

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

5755

Vitamin D3

Approved, Nutraceutical

Phase 4

67-97-0

5280795 6221

Vitamin D

Approved, Nutraceutical, Vet_approved

Phase 4

1406-16-2

Castor oil

Approved, Investigational, Nutraceutical, Vet_approved

Phase 4

8001-79-4

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

Calciferol

Phase 4

Echothiophate Iodide

Phase 4

6736-03-4

10547

Cholinesterase Inhibitors

Phase 4

Cyclooxygenase Inhibitors

Phase 4

Interventional clinical trials:

(show top 50) (show all 893)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase IV, Prospective, Open-label, Multicentre, Single Arm, 3-month Proof of Concept Study to Assess the Effect of IKERVIS® Eye Drops Administered Once Daily on the Quality of Vision in Dry Eye Disease (DED) Patients With Severe Keratitis	Unknown status	NCT03237936	Phase 4	1mg/mL ciclosporin
2	Combined Radiotherapy and Intravenous Steroids for Early Progressive Thyroid Eye Disease	Unknown status	NCT02339142	Phase 4	intravenous corticosteroids (methylprednisolone)
3	A Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy	Unknown status	NCT01969019	Phase 4	methylprednisolone, prednisone
4	An Open Label Comparing the Short Term Efficacy of Lacrisert	Unknown status	NCT03079271	Phase 4	Lacrisert, 5 Mg Ophthalmic Insert
5	A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With One Suprachoroidal Stent	Unknown status	NCT01252914	Phase 4
6	Eight Week Feasibility Study Enrolling Dry Eye Subjects Confirmed by Four of Seven Dianostic Markers Responding to Nutritional Therapy	Unknown status	NCT01561040	Phase 4
7	Effect of Intense Pulse Light (IPL) Treatment on Tear Film Osmolarity in Dry Eye Disease (DED) With Meibomian Gland Dysfunction (MGD).	Unknown status	NCT02992535	Phase 4
8	Use of Vascular Endothelial Growth Factor Inhibitor, Bevacizumab to Modulate the Outcomes of Trabeculectomy Surgery	Unknown status	NCT01229202	Phase 4	Bevacizumab
9	Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus	Unknown status	NCT00797030	Phase 4	cyclosporine and sodium carboximethycellulose;sodium carboximethycellulose
10	The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy	Unknown status	NCT01056419	Phase 4	Propylthiouracil
11	Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis.	Unknown status	NCT01669447	Phase 4
12	Echothiophate Iodide for the Prevention of Progression of Myopia	Unknown status	NCT02544529	Phase 4	Echothiophate Iodide 0.03% Ophthalmic Solution;Carboxymethylcellulose Sodium (0.5%)
13	Management of Recurrent Pterygium to Prevent Visual Impairment	Unknown status	NCT02530801	Phase 4	Bevacizumab;5 fluorouracil
14	Objective Measurements of Prolonged Effects of Restasis on Dry Eye Disease	Completed	NCT00567177	Phase 4	Restasis, Refresh Plus
15	Bromfenac 0.09% vs. Ketorolac 0.4% During the Induction Phase of Treatment With Topical Cyclosporine for Chronic Dry Eye Patients	Completed	NCT00520260	Phase 4	bromfenac;ketorolac
16	A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Dry Eye Disease	Completed	NCT01014078	Phase 4	Azithromycin Ophthalmic Solution, 1%;Placebo
17	Safety Study of the Use of Topical Cyclosporine in the Treatment of Dry Eye Disease	Completed	NCT02004067	Phase 4	Restasis;Refresh Endura
18	Effect of Lifitegrast on Dry Eye Disease Signs and Symptoms	Completed	NCT03451396	Phase 4	Lifitegrast
19	A Prospective, Multicenter, Randomized Controlled Study of the Effect of Lotepredol Etabonate on The Initiation of Dry Eye Treatment With Topical Cyclosporine	Completed	NCT00407043	Phase 4	Lotemax;Restasis
20	An 8 Week, Single Masked, Parallel-Group, Exploratory Study Comparing Ocular Surface Signs and Symptoms in Monotherapy Ocular Hypertension or Glaucoma Patients Randomized to Either Xalatan® or Travatan Z®	Completed	NCT00799682	Phase 4	Xalatan;Travatan Z
21	Prostaglandin F2-alpha Eye Drops (Bimatoprost) in Thyroid Eye Disease: a Randomised Controlled Double Blind Crossover Trial	Completed	NCT02059655	Phase 4	Bimatoprost;Eye drop solution
22	Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation	Completed	NCT03907865	Phase 4	Softacort
23	The Utility of in Vivo Confocal Microscopy (IVCM) to Assess Cellular Response and Efficacy of Long-term Topical Steroid Treatment in Patients With Dry Eye Disease (DED)	Completed	NCT02120079	Phase 4	Lotemax;Soothe Tired Eyes Lubricant Eye Drop (Artificial Tears)
24	A Prospective, Unmasked, Randomized Evaluation of the iStent Versus Two Ocular Hypotensive Agents in Patients With Primary Open-Angle Glaucoma	Completed	NCT00913029	Phase 4	latanoprost/timolol
25	Change in Optic Nerve Head Blood Flow,Optic Nerve Topography and Diurnal Fluctuation of Intraocular Pressure and Pulsatile Ocular Blood Flow in Glaucoma:Cosopt and Xalatan vs Xalatan Alone	Completed	NCT00957190	Phase 4	Dorzolamide 20 mg and Timolol 5 mg
26	A Comparison of Optive in Patients Previously Using Systane for the Treatment of Dry Eye	Completed	NCT00399230	Phase 4	Optive
27	A Prospective Evaluation of Open-angle Glaucoma Subjects on Two Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents	Completed	NCT01252888	Phase 4
28	A Prospective Evaluation of Open-angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two Trabecular Micro-bypass Stents	Completed	NCT01252862	Phase 4
29	A Prospective, Unmasked Evaluation of the iStent in Patients With Primary Open-Angle Glaucoma	Completed	NCT00911924	Phase 4
30	Multi-Center Study Comparing Efficacy and Tolerability of TRAVATAN® BAK-free (0.004% Travoprost) in Patients Previously on Latanoprost Ophthalmic Solution 0.005% Monotherapy	Completed	NCT01510145	Phase 4	Travoprost 0.004% BAK-free
31	A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.	Completed	NCT03948191	Phase 4	Methylprednisolone;99Tc-MDP(99Technetium-Methylenediphosphonate Injection)
32	Evaluation of Maintaining Visual Performance Of Subjects Who Engage in Electronic Visual Tasking While Using Restasis (EMPOWER)	Completed	NCT02554981	Phase 4	Cyclosporine 0.05% Ophthalmic Emulsion
33	Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy	Completed	NCT02121847	Phase 4	cyclosporine 0.05% ophthalmic emulsion;carboxymethylcellulose-based lubricant eye drops
34	Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in Humans	Completed	NCT00312325	Phase 4	Prednisolone
35	Safety and Efficacy of Lifitegrast 5% Ophthalmic Solution in Contact Lens Discomfort	Completed	NCT03686878	Phase 4	Lifitegrast
36	Evaluation of Tear Osmolarity Over Time With Sustained Use of Thera Tears Lubricating	Completed	NCT02758327	Phase 4	TheraTears Lubricating Eye Drops
37	An Open-label, Prospective, Multicentre, Uncontrolled, Proof of Concept Study Assessing the Efficacy of Lucentis (Ranibizumab) Administered by an Individualized "Treat and Extend" Dosing Regimen in Patients With Visual Impairment Due to Diabetic Macular Edema	Completed	NCT01297569	Phase 4	Ranibizumab
38	Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms	Completed	NCT00938704	Phase 4	carboxymethylcellulose 0.5% +glycerin 0.9%;sodium hyaluronate 0.18%
39	An Open-label, Multi-center, 6-month Extension Study Comparing the Long-term Efficacy and Safety of Lucentis (Ranibizumab) Intravitreal Injections Versus Ozurdex (Dexamethasone) Intravitreal Implant in Patients With Visual Impairment Due to Macular Edema Following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO) Who Have Completed the Respective Core Study (CRFB002EDE17 or CRFB002EDE18)	Completed	NCT01580020	Phase 4	Dexamethasone
40	Prospective, Randomized Clinical Trial of Meibomian Gland Probing Versus Sham Procedure for Refractory Meibomian Gland Dysfunction	Completed	NCT02256969	Phase 4	Blephamide;GenTeal PM Night-Time
41	An Open-Label, Single-Center Study to Evaluate Symptom Response and Tear Film Cooling Dynamics of Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)	Completed	NCT02985827	Phase 4	Rohto (r) Hydra;Systane (r) Ultra
42	Influence of Lachrymal Substitute Gels on Tear Film Thickness in Patients With Moderate to Severe Dry Eye Syndrome	Completed	NCT02585453	Phase 4
43	A 12 Months, Prospective, Multicenter, Open-label, Single Arm Interventional Study Assessing the Safety and Tolerability of 0.5 mg Ranibizumab in Mono/Bilateral Wet AMD Patients in Eyes With (Best-Corrected Distance Visual Acuity) BCVA Below 2/10 and/or Second Affected Eye	Completed	NCT01986907	Phase 4	ranibizumab
44	Lipids of the Human Tear Film and Their Effect on Tear Stability	Completed	NCT00803452	Phase 4	doxycycline;azithromycin
45	Influence of Lachrymal Substitutes on Tear Film Thickness in Patients With Moderate Dry Eye Syndrome	Completed	NCT01864330	Phase 4
46	12-Month Stability of Diurnal IOP Control on Cosopt	Completed	NCT00379834	Phase 4	Cosopt
47	Influence of Three Different Formulations of Lachrymal Substitutes on Tear Film Thickness and Other Signs and Symptoms in Patients With Moderate to Severe Dry Eye Syndrome	Completed	NCT02986750	Phase 4
48	Clinical Trial of Interventions for Visual Loss in Nursing Home Residents	Completed	NCT00348621	Phase 4
49	Steroids for Corneal Ulcers Trial	Completed	NCT00324168	Phase 4	Antibiotics;Topical corticosteroid;Placebo
50	Eliminating Trachoma With Repeat Mass Drug Treatment	Completed	NCT00322972	Phase 4	Mass treatment with oral azithromycin to an entire community

Search NIH Clinical Center for Eye Disease

Sources

Genetic Tests for Eye Disease

Genetic tests related to Eye Disease:

#	Genetic test	Affiliating Genes
1	Abnormality of the Eye ²⁹

Sources

Anatomical Context for Eye Disease

The Foundational Model of Anatomy Ontology organs/tissues related to Eye Disease:

¹⁹

Eye

MalaCards organs/tissues related to Eye Disease:

⁴⁰

Eye, Thyroid, Testes, Retina, Endothelial, Bone, T Cells

Sources

Publications for Eye Disease

Articles related to Eye Disease:

(show top 50) (show all 11206)

#	Title	Authors	PMID	Year
1	Recommendations for eye care during the alarm state by the coronavirus disease pandemic COVID-19. ⁴² ⁶¹	Gegundez-Fernandez JA...Sociedades oftalmologicas espanolas	32409243	2020
2	COVID-19 and the eye: how much do we really know? A best evidence review. ⁴²	Emparan JPO...Lansingh VC	32490972	2020
3	Efficacy and safety of Chinese medicines for vitreous hemorrhage: A protocol for systematic review and meta-analysis. ⁴²	Han M...Jin M	32384479	2020
4	Co-delivery of brinzolamide and miRNA-124 by biodegradable nanoparticles as a strategy for glaucoma therapy. ⁶¹	Li T...Zhou X	32133894	2020
5	Diabetic Retinopathy Analysis-Effects of Nanoparticle-Based Triamcinolone. ⁶¹	Du S...Wang Y	32384959	2020
6	Eye involvement in primary central nervous system lymphoma. ⁶¹	Farrall AL...Smith JR	32057762	2020
7	Early experience with teprotumumab for chronic thyroid eye disease. ⁶¹	Ozzello DJ...Korn BS	32462101	2020
8	Mixed polar-nonpolar lipid films as minimalistic models of Tear Film Lipid Layer: A Langmuir trough and fluorescence microscopy study. ⁶¹	Olzynska A...Cwiklik L	32243884	2020
9	Periorbital myxedema treated with intralesional hyaluronidase. ⁶¹	Lindgren AL...Welsh KM	32490285	2020
10	Lycium barbarum polysaccharides protects retinal ganglion cells against oxidative stress injury. ⁶¹	Liu L...Zhong JX	31997818	2020
11	A Review of Capture-recapture Methods and Its Possibilities in Ophthalmology and Vision Sciences. ⁶¹	Ramos PL...Macedo AF	32363970	2020
12	Pericyte Bridges in Homeostasis and Hyperglycemia. ⁶¹	Corliss BA...Peirce SM	32321760	2020
13	Heat-shock-induced tyrosinase gene ablation with CRISPR in zebrafish. ⁶¹	Wu YC...Wang IJ	32367255	2020
14	High resolution three-dimensional imaging of the ocular surface and intact eyeball using tissue clearing and light sheet microscopy. ⁶¹	Yang Y...Chen L	32417103	2020
15	Re: Goldberg et al.: A phase 3, randomized, double-masked study of OTX-101 ophthalmic solution 0.09% in the treatment of dry eye disease (Ophthalmology. 2019;126:1230-1237). ⁶¹	Kanda M...Nowak V	32564819	2020
16	Infrared meibography allows detection of dimensional changes in meibomian glands following intranasal neurostimulation. ⁶¹	Pondelis N...Hamrah P	32200004	2020
17	Histopathology and selective biomarker expression in human meibomian glands. ⁶¹	Reneker LW...Huang AJW	31585964	2020
18	Comparison of two intense pulsed light patterns for treating patients with meibomian gland dysfunction. ⁶¹	Wu Y...Zhao YE	32200506	2020
19	Short-Term Impact of FS-LASIK and SMILE on Dry Eye Metrics and Corneal Nerve Morphology. ⁶¹	Recchioni A...O'Donnell C	32243424	2020
20	Can Cordyceps cicadae be used as an alternative to Cordyceps militaris and Cordyceps sinensis? - A review. ⁶¹	Nxumalo W...Sun Y	32305637	2020
21	Poly(2-hydroxyethyl methacrylate)/β-cyclodextrin-hyaluronan contact lens with tear protein adsorption resistance and sustained drug delivery for ophthalmic diseases. ⁶¹	Li R...Zhao J	32339710	2020
22	Aged Mice Exhibit Severe Exacerbations of Dry Eye Disease with an Amplified Memory Th17 Cell Response. ⁶¹	Foulsham W...Dana R	32289288	2020
23	Study on the potential effective ingredients of Xiaosheng prescription for dry eye disease. ⁶¹	Wu H...Ni J	32428832	2020
24	Pigment Epithelium-derived Factor secreted by corneal epithelial cells regulates dendritic cell maturation in dry eye disease. ⁶¹	Singh RB...Dana R	32387568	2020
25	Tear inflammatory cytokines and ocular surface changes in patients with active thyroid eye disease treated with high-dose intravenous glucocorticoids. ⁶¹	Xu N...Sun F	31927748	2020
26	Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm. ⁶¹	Traish AM	32202088	2020
27	Systemic risk factors of dry eye disease subtypes: A New Zealand cross-sectional study. ⁶¹	Wang MTM...Craig JP	32311433	2020
28	Oculoplastic considerations for refractive procedures. ⁶¹	Denisova K...Barmettler A	32487809	2020
29	Diabetic Eye Disease: Advancements in Technology, Detection, and Access to Care. ⁶¹	Lyford T...Sheppard J	32456756	2020
30	Epidemiology of visual impairment, sight-threatening or treatment-requiring diabetic eye disease in children and young people in the UK: findings from DECS. ⁶¹	Ibanez-Bruron MC...Rahi JS	32536608	2020
31	Diabetic Retinopathy Screening with Automated Retinal Image Analysis in a Primary Care Setting Improves Adherence to Ophthalmic Care. ⁶¹	Liu J...Rajagopal R	32562885	2020
32	Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial. ⁶¹	Cuadrado-Lavin A...Crespo J	32493494	2020
33	The effectiveness and safety of acupuncture for patients with myopia: A protocol for a systematic review and meta-analysis. ⁶¹	Yu Z...Duan J	32501987	2020
34	A novel telemedicine technique for evaluation of ocular exam findings via smartphone images. ⁶¹	Sink J...Bouchard CS	32506998	2020
35	ATP antagonizes the crowding-induced destabilization of the human eye-lens protein γS-crystallin. ⁶¹	He Y...Song J	32307080	2020
36	Punicalagin Protects Human Retinal Pigment Epithelium Cells from Ultraviolet Radiation-Induced Oxidative Damage by Activating Nrf2/HO-1 Signaling Pathway and Reducing Apoptosis. ⁶¹	Clementi ME...Tringali G	32498245	2020
37	Profile of retinal nerve fibre layer symmetry in a multiethnic Asian population: the Singapore Epidemiology of Eye Diseases study. ⁶¹	Tao Y...Cheng CY	31558494	2020
38	An Online Prevention Tool for Ophthalmological Disorders. ⁶¹	Patte M...Mantas J	32570577	2020
39	All-trans-Retinaldehyde Contributes to Retinal Vascular Permeability in Ischemia Reperfusion. ⁶¹	Dreffs A...Antonetti DA	32492112	2020
40	PRICKLE3 linked to ATPase biogenesis manifested Leber's hereditary optic neuropathy. ⁶¹	Yu J...Guan MX	32516135	2020
41	Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidines as atypical protein kinase C inhibitors to control retinal vascular permeability and cytokine-induced edema. ⁶¹	Liu X...Antonetti DA	32327351	2020
42	A Novelty Route for Smartphone-based Artificial Intelligence Approach to Ophthalmic Screening. ⁶¹	Jheng YC...Hwang DK	32520771	2020
43	Evaluation of eye movements and visual performance in patients with cataract. ⁶¹	Wan Y...Li X	32555224	2020
44	Enrollment in the Zoster Eye Disease Study. ⁶¹	Cohen EJ...Gillespie C	32558726	2020
45	Health information needs regarding diabetes mellitus in China: an internet-based analysis. ⁶¹	Wang TH...Pan ZG	32576159	2020
46	Comparative Analysis of Age-Related Changes in Lacrimal Glands and Meibomian Glands of a C57BL/6 Male Mouse Model. ⁶¹	Yoon CH...Kim MK	32545199	2020
47	The effect of astaxanthin on inflammation in hyperosmolarity of experimental dry eye model in vitro and in vivo. ⁶¹	Li H...Wang Q	32531188	2020
48	Deep lateral rim-sparing orbital wall decompression in spontaneous globe subluxation associated with shallow orbits and eyelids laxity. ⁶¹	Bengoa-Gonzalez A...Lago-Llinas MD	31392912	2020
49	Diagnosis and remediation of blink inefficiency. ⁶¹	McMonnies CW	32499135	2020
50	Clinical and in vivo confocal microscopic features of neuropathic corneal pain. ⁶¹	Ross AR...Said DG	31533927	2020

Sources

Genes for Eye Disease

Genes related to Eye Disease (6 elite genes):

(show top 50) (show all 278)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	CNGB3	Cyclic Nucleotide Gated Channel Subunit Beta 3	Protein Coding	407.74	Pathogenic/Likely pathogenic ⁶ DISEASES inferred ¹⁵
2	CNGA3	Cyclic Nucleotide Gated Channel Subunit Alpha 3	Protein Coding	407.72	Pathogenic ⁶ DISEASES inferred ¹⁵
3	RDH12	Retinol Dehydrogenase 12	Protein Coding	407.57	Pathogenic ⁶ DISEASES inferred ¹⁵
4	IMPG2	Interphotoreceptor Matrix Proteoglycan 2	Protein Coding	406.52	Pathogenic ⁶ DISEASES inferred ¹⁵
5	ABCC6	ATP Binding Cassette Subfamily C Member 6	Protein Coding	406.52	Pathogenic ⁶ DISEASES inferred ¹⁵
6	VPS13B	Vacuolar Protein Sorting 13 Homolog B	Protein Coding	405.71	Pathogenic ⁶ DISEASES inferred ¹⁵
7	CACNA1F	Calcium Voltage-Gated Channel Subunit Alpha1 F	Protein Coding	50.25	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Gene name Summaries Variants (show sections)
8	LCAT	Lecithin-Cholesterol Acyltransferase	Protein Coding	41.02	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications Summaries Variants (show sections)
9	CFH	Complement Factor H	Protein Coding	23.54	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
10	ABCA4	ATP Binding Cassette Subfamily A Member 4	Protein Coding	23.26	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
11	ARMS2	Age-Related Maculopathy Susceptibility 2	Protein Coding	23.06	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
12	NPHP1	Nephrocystin 1	Protein Coding	22.46	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Summaries (show sections)
13	C3	Complement C3	Protein Coding	21.77	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
14	CFB	Complement Factor B	Protein Coding	21.64	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
15	HTRA1	HtrA Serine Peptidase 1	Protein Coding	21.25	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
16	C2	Complement C2	Protein Coding	20.86	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders Publications (show sections)
17	BPIFA1	BPI Fold Containing Family A Member 1	Protein Coding	18.25	DISEASES inferred ¹⁵ GeneCards inferred via : Publications Functions (show sections)
18	ERCC6	ERCC Excision Repair 6, Chromatin Remodeling Factor	Protein Coding	18.25	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Disorders (show sections)
19	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	15.97	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	TNF	Tumor Necrosis Factor	Protein Coding	15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
21	CEP290	Centrosomal Protein 290	Protein Coding	14.9	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
22	PAX6	Paired Box 6	Protein Coding	14.83	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
23	ROM1	Retinal Outer Segment Membrane Protein 1	Protein Coding	14.75	DISEASES inferred ¹⁵ GeneCards inferred via : Summaries (show sections)
24	IL6	Interleukin 6	Protein Coding	14.63	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
25	IL1B	Interleukin 1 Beta	Protein Coding	14.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
26	CRYAA	Crystallin Alpha A	Protein Coding	14.46	DISEASES inferred ¹⁵ ¹⁵
27	SFTA3	Surfactant Associated 3	RNA Gene	14.37	DISEASES inferred ¹⁵ GeneCards inferred via : Functions (show sections)
28	IL10	Interleukin 10	Protein Coding	14.18	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
29	OAT	Ornithine Aminotransferase	Protein Coding	14.12	DISEASES inferred ¹⁵ GeneCards inferred via : Summaries (show sections)
30	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	14.12	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
31	IGF1	Insulin Like Growth Factor 1	Protein Coding	13.92	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
32	IL2	Interleukin 2	Protein Coding	13.9	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
33	CFI	Complement Factor I	Protein Coding	13.89	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
34	EGF	Epidermal Growth Factor	Protein Coding	13.88	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
35	CX3CR1	C-X3-C Motif Chemokine Receptor 1	Protein Coding	13.83	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
36	CCL2	C-C Motif Chemokine Ligand 2	Protein Coding	13.76	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
37	COL2A1	Collagen Type II Alpha 1 Chain	Protein Coding	13.66	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
38	IFNG	Interferon Gamma	Protein Coding	13.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
39	IL17A	Interleukin 17A	Protein Coding	13.6	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
40	NPHP4	Nephrocystin 4	Protein Coding	13.58	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
41	IQCB1	IQ Motif Containing B1	Protein Coding	13.56	DISEASES inferred ¹⁵ GeneCards inferred via : Disorders (show sections)
42	KDR	Kinase Insert Domain Receptor	Protein Coding	13.55	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
43	BDNF	Brain Derived Neurotrophic Factor	Protein Coding	13.53	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
44	IL4	Interleukin 4	Protein Coding	13.49	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
45	CYP1B1	Cytochrome P450 Family 1 Subfamily B Member 1	Protein Coding	13.33	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
46	IL13	Interleukin 13	Protein Coding	13.28	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
47	FLT1	Fms Related Receptor Tyrosine Kinase 1	Protein Coding	13.26	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
48	MMP2	Matrix Metallopeptidase 2	Protein Coding	13.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
49	IL5	Interleukin 5	Protein Coding	13.24	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
50	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	13.23	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Eye Disease

ClinVar genetic disease variations for Eye Disease:

⁶ (show all 29) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	GRCh37 Pos	GRCh38 Pos
1	IMPG2	NM_016247.4(IMPG2):c.1680T>A (p.Tyr560Ter)	SNV	Pathogenic	437938	rs758291149	3:100963495-100963495	3:101244651-101244651
2	CNGB3	NM_019098.4(CNGB3):c.1810C>T (p.Arg604Ter)	SNV	Pathogenic	438042	rs200805087	8:87591452-87591452	8:86579224-86579224
3	ABCC6	NM_001171.5(ABCC6):c.4104del (p.Asp1368fs)	deletion	Pathogenic	433350	rs72664237	16:16248589-16248589	16:16154732-16154732
4	RDH12	NM_152443.3(RDH12):c.806_810del (p.Ala269fs)	deletion	Pathogenic	2047	rs386834261	14:68196054-68196058	14:67729337-67729341
5	VPS13B	NM_017890.4(VPS13B):c.2591C>A (p.Ser864Ter)	SNV	Pathogenic	95840	rs140936527	8:100286501-100286501	8:99274273-99274273
6	CNGA3	NM_001298.3(CNGA3):c.1688G>A (p.Arg563His)	SNV	Pathogenic	265467	rs552069173	2:99013321-99013321	2:98396858-98396858
7	VPS13B	NM_017890.4(VPS13B):c.6370_6371del (p.Met2124fs)	deletion	Pathogenic/Likely pathogenic	242548	rs748404277	8:100712001-100712002	8:99699773-99699774
8	CNGB3	NM_019098.4(CNGB3):c.1285del (p.Ser429fs)	deletion	Pathogenic/Likely pathogenic	427658	rs776896038	8:87645015-87645015	8:86632787-86632787
9	ABCC6	NM_001171.5(ABCC6):c.3389C>T (p.Thr1130Met)	SNV	Pathogenic/Likely pathogenic	6569	rs63750459	16:16256967-16256967	16:16163110-16163110
10	GNAT2	NM_005272.4(GNAT2):c.906C>A (p.Tyr302Ter)	SNV	Likely pathogenic	438058	rs1553226355	1:110146135-110146135	1:109603513-109603513
11	CNGA3	NM_001298.3(CNGA3):c.107_110del (p.His36fs)	deletion	Likely pathogenic	438155	rs749036398	2:98994154-98994157	2:98377691-98377694
12	RBP4	NM_006744.4(RBP4):c.248+1G>A	SNV	Likely pathogenic	438114	rs111785373	10:95360423-95360423	10:93600666-93600666
13	TYR	NM_000372.5(TYR):c.1037G>T (p.Gly346Val)	SNV	Likely pathogenic	437986	rs773970123	11:88960991-88960991	11:89227823-89227823
14	RPGRIP1	NM_020366.3(RPGRIP1):c.2398G>A (p.Glu800Lys)	SNV	Likely pathogenic	438161	rs565837539	14:21794020-21794020	14:21325861-21325861
15	NR2E3	NM_014249.4(NR2E3):c.305C>A (p.Ala102Asp)	SNV	Likely pathogenic	438227	rs772881093	15:72104165-72104165	15:71811825-71811825
16	NYX	NM_022567.2(NYX):c.936C>G (p.Asn312Lys)	SNV	Likely pathogenic	438056	rs1555967263	X:41333642-41333642	X:41474389-41474389
17	RP2	NM_006915.3(RP2):c.43del (p.Ser15fs)	deletion	Likely pathogenic	437945	rs1556313474	X:46696578-46696578	X:46837143-46837143
18	CACNA1F	NM_001256789.3(CACNA1F):c.3595C>T (p.Gln1199Ter)	SNV	Likely pathogenic	438125	rs782362725	X:49071548-49071548	X:49215088-49215088
19	CHM	NM_000390.4(CHM):c.315-1536A>G	SNV	Likely pathogenic	438064	rs1555955061	X:85220593-85220593	X:85965588-85965588
20	AHI1	NM_001134831.2(AHI1):c.1912+1488_2036+506del	deletion	Likely pathogenic	438231		6:135759007-135762232	6:135437869-135441094
21	TRPM6		deletion	Likely pathogenic	438256		9:77388717-77398576	9:74773801-74783660
22	subset of 27 genes: PRRT2	GRCh37/hg19 16p11.2(chr16:29656684-30197341)	copy number gain	Likely pathogenic	523255		16:29656684-30197341
23	CNGB3	NM_019098.4(CNGB3):c.1148del (p.Thr383fs)	deletion	Conflicting interpretations of pathogenicity	5225	rs397515360	8:87656009-87656009	8:86643781-86643781
24	CNGB3	NM_019098.4(CNGB3):c.1208G>A (p.Arg403Gln)	SNV	Conflicting interpretations of pathogenicity	143154	rs147876778	8:87645092-87645092	8:86632864-86632864
25	CACNA2D4	NM_172364.5(CACNA2D4):c.1882C>T (p.Arg628Ter)	SNV	Uncertain significance	208566	rs200098356	12:1969369-1969369	12:1860203-1860203
26		46;XX;inv(6)(p11.1q21)dn	inversion	Uncertain significance	268013
27	VPS13B	NM_017890.4(VPS13B):c.3628G>T (p.Asp1210Tyr)	SNV	Uncertain significance	95847	rs145417421	8:100479824-100479824	8:99467596-99467596
28	AIFM3 , CRKL , LZTR1 , P2RX6 , PI4KA , SERPIND1 , SLC7A4 , SNAP29 , THAP7	GRCh37/hg19 22q11.21(chr22:21081260-21431174)	copy number gain	Uncertain significance	523275		22:21081260-21431174
29	TRHR	GRCh37/hg19 8q23.1(chr8:109990022-110168343)	copy number loss	Uncertain significance	523291		8:109990022-110168343

Sources

Expression for Eye Disease

Search GEO for disease gene expression data for Eye Disease.

Sources

Pathways for Eye Disease

Pathways related to Eye Disease according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Immune response Lectin induced complement pathway ²² Show member pathways Activation of C3 and C5 ⁶⁵ Complement Activation Pathways ⁶⁶ Immune response Alternative complement pathway ²² Immune response Classical complement pathway ²² Regulation of Complement cascade ⁶⁵	11.76	CFH CFB C3 C2
2	Creation of C4 and C2 activators ⁶⁵ Show member pathways Alternative complement activation ⁶⁵ Classical antibody-mediated complement activation ⁶⁵ Complement cascade ⁶⁵ Ficolins bind to repetitive carbohydrate structures on the target cell surface ⁶⁵ Initial triggering of complement ⁶⁵ Lectin pathway of complement activation ⁶⁵ Terminal pathway of complement ⁶⁵	11.62	CFH CFB C3 C2
3	Complement Pathway ⁶³ Show member pathways Alternative Complement Pathway ⁶³ Classical Complement Pathway ⁶³ Complement Activation ¹ Lectin Induced Complement Pathway ⁶³	11.45	CFB C3 C2
4	Complement and coagulation cascades ³⁶ ¹	11.42	CFH CFB C3 C2
5	Pertussis ³⁶	11.38	TNF C3 C2
6	Staphylococcus aureus infection ³⁶	10.91	CFH CFB C3 C2

Sources

GO Terms for Eye Disease

Cellular components related to Eye Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular region	GO:0005576	9.85	VEGFA TNF LCAT IMPG2 HTRA1 CFH
2	extracellular space	GO:0005615	9.61	VEGFA TNF LCAT HTRA1 CFH CFB
3	photoreceptor outer segment	GO:0001750	9.43	CNGB3 CACNA1F ABCA4
4	transmembrane transporter complex	GO:1902495	8.62	CNGB3 CNGA3

Biological processes related to Eye Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	innate immune response	GO:0045087	9.83	CFH CFB C3 C2 BPIFA1
2	response to stimulus	GO:0050896	9.8	RDH12 CNGB3 CNGA3 CACNA1F ABCC6 ABCA4
3	regulation of complement activation	GO:0030449	9.56	CFH CFB C3 C2
4	photoreceptor cell maintenance	GO:0045494	9.54	RDH12 ERCC6 ABCA4
5	complement activation	GO:0006956	9.46	CFH CFB C3 C2
6	positive regulation of apoptotic cell clearance	GO:2000427	9.4	C3 C2
7	visual perception	GO:0007601	9.17	RDH12 IMPG2 CNGB3 CNGA3 CACNA1F ABCC6
8	complement activation, alternative pathway	GO:0006957	9.13	CFH CFB C3

Molecular functions related to Eye Disease according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cGMP binding	GO:0030553	9.16	CNGB3 CNGA3
2	intracellular cAMP-activated cation channel activity	GO:0005222	8.96	CNGB3 CNGA3
3	intracellular cGMP-activated cation channel activity	GO:0005223	8.62	CNGB3 CNGA3

Sources

Sources for Eye Disease

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia